NASDAQ: FOLDAmicus Therapeutics Inc Stock
$10.28+0.11 (+1.08%)
Updated Apr 26, 2024
FOLD Price
$10.28
Fair Value Price
N/A
Market Cap
$3.04B
52 Week Low
$9.70
52 Week High
$14.57
P/E
-20.16x
P/B
18.96x
P/S
10.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$399.36M
Earnings
-$151.58M
Gross Margin
90.7%
Operating Margin
-25.03%
Profit Margin
-38%
Debt to Equity
3.86
Operating Cash Flow
-$69M
Beta
1.24
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FOLD Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FOLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FOLD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FOLD is poor value based on its book value relative to its share price (18.96x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
FOLD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FOLD due diligence checks available for Premium users.
Be the first to know about important FOLD news, forecast changes, insider trades & much more!
FOLD News
Valuation
FOLD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.16x
Industry
14.88x
Market
41.14x
FOLD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
18.96x
Industry
5.85x
FOLD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FOLD's financial health
Profit margin
Revenue
$115.1M
Net Income
-$33.8M
Profit Margin
-29.4%
FOLD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FOLD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$777.9M
Liabilities
$617.7M
Debt to equity
3.86
FOLD's short-term assets ($483.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FOLD's short-term assets ($483.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FOLD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FOLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.5M
Investing
-$24.0M
Financing
$8.2M
FOLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FOLD vs Biotech Stocks
Amicus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.